Merck & Co., Inc. (NYSE: MRK) receives FDA Breakthrough Therapy Designation for raludotatug deruxtecan for platinum-resistant ovarian cancer. The drug targets CDH6, showing promise for patients with significant unmet needs. This marks a milestone in the Merck & Co., Inc. – Daiichi Sankyo oncology collaboration.

Merck & Co., Inc. (NYSE: MRK), a global healthcare company, is recognized for developing pharmaceuticals, vaccines, biologics, and animal health products. It is considered one of the 15 Best Stocks to Invest in for Financial Stability.

While Merck & Co., Inc. (NYSE: MRK) is a strong investment option, there are AI stocks with greater upside potential and lower downside risk. For those seeking undervalued AI stocks poised to benefit from current trends, consider exploring opportunities in the AI sector.

Read more at Yahoo Finance: FDA Grants Breakthrough Therapy Designation to Merck & Co., Inc. (MRK)’s Raludotatug Deruxtecan for Platinum-Resistant Ovarian